Adalimumab in JIA-associated Uveitis Stopping Trial

Inclusion Criteria (must meet all of the following to qualify): * Stated willingness to comply with all study procedures and availability for the duration of the study period * ≥ 2 years of age * History of JIA or CAU diagnosed prior to 16 years of age (patient may be older than 16 at time of enrollment) * Formal diagnosis of JIA-associated uveitis or CAU with no other suspected etiology * ≥12 consecutive months of controlled ocular inflammation (≤0.5+ anterior chamber cell, ≤0.5+ vitreous haze, no active retinal/choroidal lesions in either eye) * ≥ 12 consecutive months of controlled arthritis verified by a pediatric rheumatologist, if defined as JIA-associated uveitis * ≥12 consecutive months of treatment with adalimumab or a biosimilar of adalimumab * ≥180 days on a stable dose of adalimumab or a biosimilar; must be biweekly dose of either 20mg (if\<30kg) or 40mg (if ≥30kg) * If on a biosimilar of adalimumab, ≥90 days on the biosimilar * If on concomitant antimetabolite (injectable or oral methotrexate, mycophenolate mofetil, azathioprine, or leflunomide), dose must be ≤25 mg weekly for methotrexate, ≤3 g daily for mycophenolate mofetil, ≤250 mg daily for azathioprine, or ≤20 mg daily for leflunomide; dose and route of administration must be stable for ≥90 days * If on topical corticosteroids, dose must be ≤2 drops prednisolone acetate 1% or equivalent per day and stable for ≥90 days * Willingness to limit consumption of alcohol during the study period * Agreement to avoi…